Takeda Pharmaceutical Company Limited (4502)
Summary of Financial Statements for the Nine Month
Period Ended December 31, 2014 (Consolidated)
(6) Development activities
Note: This table primarily shows the indications for which we will actively pursue approval. We are also conducting additional studies of
certain assets to examine their potential for use in further indications.

As of February 5, 2015
US/EU/Jpn
Development
Drug Class
In-house/
Indications
Stage
Ulcerative colitis
US
EU
Jpn
Approved (May 14)
Approved (May 14)
P-III
Crohn’s disease
US
EU
Jpn
Approved (May 14)
Approved (May 14)
P-III
Subcutanous formulation
-
P-I
Potassium-competitive acid
blocker (oral)
Acid-related diseases
Jpn
Approved (Dec 14)
In-house
Mu-opioid receptor antagonist
and dopamine/norepinephrine
re-uptake inhibitor (oral)
Obesity
US
Approved (Sep 14)
In-license
(Orexigen)
<fomepizole>
Alcohol dehydrogenase
inhibitor (injection)
Ethylene glycol and methanol poisonings
Jpn
Approved (Sep 14)
In-license
(Paladin Labs)
SYR-472
<trelagliptin>
DPP-4 inhibitor
(oral)
Type 2 diabetes
Jpn
Filed (Mar 14)
In-house
Hib vaccine
(injection)
Prevention of infectious disease caused by
Haemophilus influenzae type b (Hib)
Jpn
Filed (Sep 13)
In-license
(Novartis)
Immunomodulator (injection)
Relapse prevention of multiple sclerosis
Jpn
Filed (Dec 14)
In-license
(Teva)
Previously untreated multiple myeloma
US
EU
Jpn
P-III
P-III
P-III
Relapsed or refractory multiple myeloma
US
EU
Jpn
P-III
P-III
P-III
Relapsed or refractory primary (AL)
amyloidosis
US
EU
P-III
P-III
Maintenance therapy in patients with multiple
myeloma following autologous stem cell
transplant
US
EU
P-III
P-III
Solid tumors
US
P-I
Relapsed or refractory peripheral T-cell
lymphoma
US
EU
P-III
P-III
Small cell lung cancer, Ovarian cancer
US
EU
P-II
P-II
Non-Hodgkin lymphoma
Jpn
P-I
Solid tumors
Jpn
P-I
code/product name
<generic name>
MLN0002
<vedolizumab>
TAK-438
<vonoprazan>
®
Contrave
<naltrexone XR
/bupropion XR>
TAK-816
<glatiramer acetate>
MLN9708
<ixazomib>
(administration route)
Humanized monoclonal
antibody against α4β7 integrin
(injection)
Proteasome inhibitor
(oral)
MLN8237
<alisertib>
Aurora A kinase inhibitor
(oral)
1
Lu AA21004*
<vortioxetine>
Multimodal anti-depressant
(oral)
Major depressive disorder
<motesanib
diphosphate>
VEGFR1-3, PDGFR, c-Kit
inhibitor (oral)
Advanced non-squamous non-small cell
lung cancer
AMG 386
<trebananib>
Anti-angiopoietin peptibody
(injection)
<rasagiline>
Monoamine oxidase B (MAO-B)
inhibitor (oral)
In-license
In-house
In-house
In-house
P-III
In-license
(Lundbeck)
Jpn
P-III
In-license
(Amgen)
Ovarian cancer
Jpn
P-III
In-license
(Amgen)
Parkinson's disease
Jpn
P-III
In-license
(Teva)
Jpn
*1 Additional indications being pursued in the US have been moved to the section "Additional indications/formulations of approved compounds"
- 31 -
Takeda Pharmaceutical Company Limited (4502)
Summary of Financial Statements for the Nine Month
Period Ended December 31, 2014 (Consolidated)
Development
code/product name
<generic name>
MLN0264
<->
TAK-385
<relugolix>
MLN0128
<->
2
TAK-003*
3
TAK-214*
4
TAK-114*
MT203
<namilumab>
Drug Class
In-house/
In-license
Indications
Stage
Gastric cancer, Pancreatic cancer
US
EU
P-II
P-II
Prostate cancer
US
EU
Jpn
P-II
P-II
P-I
Endometriosis
Jpn
P-II
Uterine fibroids
Jpn
P-II
Breast cancer
US
EU
P-II
P-II
Solid tumors
-
P-I
Tetravalent dengue vaccine
(injection)
Prevention of dengue fever caused by
dengue virus
-
P-II
In-house
Norovirus vaccine
(injection)
Prevention of acute gastroenteritis (AGE)
caused by norovirus
-
P-II
In-house
Pro-inflammatory cytokine
inhibitor (oral)
Ulcerative colitis
US
EU
Jpn
P-II
P-II
P-I
In-license
(Natrogen)
Psoriasis
EU
P-II
Rheumatoid arthritis
EU
Jpn
P-I
P-I
(administration route)
Antibody-Drug Conjugate
targeting GCC (injection)
LH-RH antagonist
(oral)
mTORC1/2 inhibitor (oral)
GM-CSF monoclonal antibody
(injection)
In-house
In-house
In-house
In-licence
(Amgen)
Early stage diabetic nephropathy
Jpn
P-II
Hypertension
-
P-I
Influenza vaccine
(injection)
Prevention of influenza disease caused by
influenza virus subtype A and B contained in
the vaccine
Jpn
P-I/II
In-license
(Baxter)
TAK-733
<->
MEK inhibitor
(oral)
Solid tumors
-
P-I
In-house
TAK-063
<->
PDE10A inhibitor (oral)
Schizophrenia
-
P-I
In-house
TAK-137
<->
AMPA receptor potentiator
(oral)
Psychiatric disorders and neurological
diseases
-
P-I
In-house
TAK-659
<->
SYK kinase inhibitor (oral)
Solid tumors, Hematologic malignancies
-
P-I
In-house
TAK-233
<->
(oral)
-
-
P-I
In-house
TAK-935
<->
CH24H inhibitor (oral)
Diseases related to glutamate excitotoxicity
-
P-I
In-house
TAK-058
<->
5-HT3 receptor antagonist
(oral)
Schizophrenia, especially cognitive
impairment associated with schizophrenia
-
P-I
In-house
TAK-079
<->
Cytolytic monoclonal antibody
(injection)
Rheumatoid arthritis, Systemic lupus
erythematosus
-
P-I
In-house
INV21
EV71 vaccine (injection)
Prevention of hand, foot and mouth disease
caused by enterovirus 71
-
P-I
In-house
MLN3126
<->
CCR9 antagonist (oral)
Sjogren's syndrome
-
P-I
In-house
MLN4924
<->
NEDD 8 activating enzyme
inhibitor (injection)
Advanced malignancies, Acute myeloid
leukemia
-
P-I
In-house
MLN1117
<->
PI3Kα isoform inhibitor (oral)
Solid tumors
-
P-I
In-house
TAK-272
<->
Direct renin inhibitor
(oral)
TAK-850
In-house
*2 Formerly known as DENVax
*3 Formerly known as Norovirus vaccine
*4 Formerly known as Natura-alpha
- 32 -
Takeda Pharmaceutical Company Limited (4502)
Summary of Financial Statements for the Nine Month
Period Ended December 31, 2014 (Consolidated)
Development code/
product name
<generic name>
(administration route)
Indications
Stage
In-house/
In-license
MLN7243
<->
UAE Inhibitor (injection)
Solid tumors
-
P-I
In-house
MLN2480
<->
pan-Raf kinase inhibitor
(oral)
Solid tumors
-
P-I
In-license
(Sunesis)
Multimodal anti-depressant
(oral)
Major depressive disorder, Generalized
anxiety disorder
US
Jpn
P-I
P-I
In-license
(Lundbeck)
Human monoclonal antibody
against human Nerve Growth
Factor (NGF) (injection)
Pain
Jpn
P-I
In-license
(Amgen)
Lu AA24530
<->
AMG 403
<fulranumab>

Drug Class
Additional indications/formulations of approved compounds
Development code
<generic name>
Brand name
(country / region)
Drug Class
In-house/
In-license
Indications or formulations
Stage
Retreatment of multiple myeloma
US
Approved (Aug 14)
Front line mantle cell lymphoma
US
Approved (Oct 14)
<bortezomib>
®
Velcade (US)
Proteasome inhibitor
TAP-144-SR
<leuprorelin acetate>
®
Leuplin (Jpn)
®
Lupron Depot (US)
®
Enantone , etc. (EU)
LH-RH agonist
Prostate cancer, Premenopausal breast
cancer (6-month formulation)
Jpn
Filed (Sep 14)
In-house
TAK-375SL
<ramelteon>
®
Rozerem (US, Jpn)
MT1/MT2 receptor
agonist
Bipolar (sublingual formulation)
US
P-III
In-house
SYR-322
<alogliptin>
®
Nesina (US, Jpn)
®
Vipidia (EU)
DPP-4 inhibitor
Type 2 diabetes (fixed-dose combination
with metformin)
Jpn
P-III
In-house
AD-4833/TOMM40
Insulin sensitizer/
Biomarker assay
Delay of onset of mild cognitive impairment
due to Alzheimer's disease
US
EU
P-III
P-III
In-license
(Zinfandel)
Relapsed cutaneous T-cell lymphoma
EU
P-III
Post-ASCT Hodgkin lymphoma
EU
P-III
Front line Hodgkin lymphoma
EU
Jpn
P-III
P-III
Front line mature T-cell lymphoma
EU
Jpn
P-III
P-III
In-house
SGN-35
<brentuximab
vedotin>
®
Adcetris (EU, Jpn)
CD30 monoclonal antibody-drug
conjugate
Lu AA21004
<vortioxetine>
®
Brintellix (US)
Generalized anxiety disorder
US
P-III
Multimodal anti-depressant
Attention Deficit Hyperactivity Disorder
(ADHD) in adult patients
US
P-II
<lubiprostone>
®
Amitiza (US)
Chloride channel
activator
New formulation
US
P-III
Pediatric functional constipation
US
P-III
<febuxostat XR>
®
Uloric (US)
Non-purine, selective xanthine
oxidase inhibitor
Extended-release formulation
US
P-III
In-license
(Teijin)
<lurasidone
hydrochloride>
®
Latuda (EU)
Atypical antipsychotic agent
Bipolar disorder
EU
P-III
In-license
(Sumitomo
Dainippon
Pharma)
TAK-390MROD
<dexlansoprazole>
®
Dexilant (US)
Proton pump inhibitor
Orally disintegrating tablet
-
P-I
In-house
- 33 -
In-license
(Seattle
Genetics)
In-license
(Lundbeck)
In-license
(Sucampo)
Takeda Pharmaceutical Company Limited (4502)
Summary of Financial Statements for the Nine Month
Period Ended December 31, 2014 (Consolidated)

Recent progress in stage
Development code
<generic name>
th
Progress in stage since release of FY2013 results (May 8 , 2014)
Indications
Country/Region
Progress in stage
MLN0002
<vedolizumab>
Ulcerative colitis
US
Approved (May 14)
MLN0002
<vedolizumab>
Crohn's disease
US
Approved (May 14)
MLN0002
<vedolizumab>
Ulcerative colitis
EU
Approved (May 14)
MLN0002
<vedolizumab>
Crohn's disease
EU
Approved (May 14)
Retreatment of multiple myeloma
US
Approved (Aug 14)
Obesity
US
Approved (Sep 14)
<fomepizole>
Ethylene glycol and methanol poisonings
Jpn
Approved (Sep 14)
<bortezomib>
Front line mantle cell lymphoma
US
Approved (Oct 14)
Prostate cancer, Premenopausal breast cancer (6-month formulation)
Jpn
Filed (Sep 14)
MLN9708
<ixazomib>
Maintenance therapy in patients with multiple myeloma following
autologous stem cell transplant
US, EU
P-III
SYR-322
<alogliptin>
Type 2 diabetes (fixed-dose combination with metformin)
Jpn
P-III
Gastric cancer, Pancreatic cancer
US, EU
P-II
Prostate cancer
EU
P-II
Breast cancer
EU
P-II
Subcutaneous formulation
-
P-I
TAK-935
<->
Diseases related to glutamate excitotoxicity
-
P-I
TAK-058
<->
Schozophrenia, especially cognitive impairment associated
with schizophrenia
-
P-I
MLN4924
<->
Acute myeloid leukemia
-
P-I
TAK-079
<->
Rheumatoid arthritis, Systemic lupus erythematosus
-
P-I
MLN3126
<->
Sjogren's syndrome
-
P-I
Prostate cancer
Jpn
P-I
Acid-related diseases
Jpn
Approved (Dec 14)
Relapse prevention of multiple sclerosis
Jpn
Filed (Dec 14)
Parkinson's disease
Jpn
P-III
Attention Deficit Hyperactivity Disorder (ADHD) in adult patients
US
P-II
Early stage diabetic nephropathy
Jpn
P-II
Rheumatoid arthritis
Jpn
P-I
<bortezomib>
®
Contrave
<naltrexone XR /
bupropion XR>
TAP-144-SR
<leuprorelin acetate>
MLN0264
<->
TAK-385
<relugolix>
MLN0128
<->
MLN0002
<vedolizumab>
TAK-385
<relugolix>
TAK-438
<vonoprazan>
<glatiramer acetate>
<rasagiline>
Lu AA21004
<vortioxetine>
TAK-272
MT203
<namilumab>
th
Progress in stage since the announcement of FY2014 Q2 results (October 30 , 2014) are listed under the bold dividing line
- 34 -
Takeda Pharmaceutical Company Limited (4502)
Summary of Financial Statements for the Nine Month
Period Ended December 31, 2014 (Consolidated)

Revised collaboration agreement
th
Revised since release of FY2013 results (May 8 , 2014)
Development code/
product name
Indications (Stage)
Reason
Iron deficiency anemia from all causes in patients
who have a history of unsatisfactory oral iron
therapy or in whom oral iron cannot be used
(EU, Filed)
Following a strategic product portfolio review, ferumoxytol no longer fits within
Takeda’s current strategy. Takeda and AMAG announced in December 2014
that they have entered into an agreement to mutually terminate the March 2010
license, development and commercialization agreement, which granted Takeda
exclusive rights to market ferumoxytol in Canada, the European Union and
Switzerland, as well as certain other geographic territories.
Cognitive impairment associated with
schizophrenia (P-I)
Based on a prioritization of Takeda’s portfolio, the companies agreed to return
the program to Intra-Cellular Therapies so it could continue development.
<generic name>
®
®
Rienso / Feraheme
<ferumoxytol>
ITI-214
<->
th
Revised collaboration agreements since the announcement of FY2014 Q2 results (October 30 , 2014) are listed under the bold dividing line

Discontinued projects
Development code
<generic name>
SYR-472
<trelagliptin>
TAK-700
<orteronel>
<peginesatide>
TAK-361S
th
Discontinued since release of FY2013 results (May 8 , 2014)
Indications (Stage)
Reason
Type 2 diabetes (US, EU P-II)
Discontinued in the US and EU after consideration of the development costs that
would be necessary in order to obtain approval.
Prostate cancer (US, EU, Jpn P-III)
Takeda decided to end the development program for orteronel (TAK-700) based
on the results of two Phase 3 clinical trials. The studies found that while
orteronel plus prednisone could extend the time patients lived before their
cancer progressed, it did not extend overall survival in these patients.
Anaemia associated with chronic kidney disease
in adult patients undergoing dialysis (EU P-III)
In February 2013, all lots of peginesatide were voluntarily recalled in the US
following postmarketing reports of serious hypersensitivity reactions. A detailed
investigation of these reactions has confirmed that no quality or manufacturing
issues were present but has not identified a specific root cause for the reactions.
Based on these findings, further clinical development of peginesatide will not be
pursued.
Prevention of infectious disease caused by
diphtheria, pertussis, tetanus, poliomyelitis
(Jpn P-II)
Takeda decided to voluntarily discontinue the development of TAK-361S to shift
development resources to allow Takeda to focus on vaccine programs that
address significant unmet needs.
th
Discontinued projects since the announcement of FY2014 Q2 results (October 30 , 2014) are listed under the bold dividing line

Filings and Approvals in Brazil, China & Russia
Takeda is steadily progressing its pipeline assets through the filing and approval process on a global scale, including in emerging
markets. This table shows filings and approvals in the key emerging markets of Brazil, China & Russia.
Country
Development code/generic name (stage)
5
6
Brazil
TAK-491* /chlorthalidone (Approved Jul 14), SGN-35 (Approved Sep 14), mifamurtide* (Approved Oct 14),
7
SYR-322/metformin (Filed Jul 13), SYR-322/pioglitazone (Filed Dec 13), TAK-375* (Filed Mar 14), MLN0002 (Filed Sep 14)
China
roflumilast* (Filed Dec 11), SGN-35 (Filed May 13)
8
9
TAK-390MR* (Approved May 14), SYR-322 (Approved Oct 14), SYR-322/metformin (Filed Mar 14), SGN-35 (Filed May 14),
TAK-491/chlorthalidone (Filed May 14), lurasidone (Filed Dec 14)
*5 TAK-491 <azilsartan medoxomil> Angiotensin II receptor blocker (oral) for the treatment of hypertension
*6 <mifamurtide> Immunostimulant (injection) for the treatment of non-metastatic osteosarcoma
*7 TAK-375 <ramelteon> MT1/MT2 receptor agonist (oral) for the treatment of insomnia
*8 <roflumilast> PDE4 inhibitor (oral) for the treatment of Chronic Obstructive Pulmonary Disease
*9 TAK-390MR <dexlansopraxole> Proton pump inhibitor (oral) for the treatment of erosive esophagitis and gastro-esopageal reflux disease
Russia
- 35 -